Quantitative CT and (19)F-MRI tracking of perfluorinated encapsulated mesenchymal stem cells to assess graft immunorejection Journal Article

Local Library Link: Find It @ Loyola

Authors: Wang, G; Fu, Y; Shea, S. M.; Hegde, S. S.; Kraitchman, D. L.
Article Title: Quantitative CT and (19)F-MRI tracking of perfluorinated encapsulated mesenchymal stem cells to assess graft immunorejection
Abstract: OBJECTIVES: Peripheral artery disease (PAD) affects 12-14% of the world population, and many are not eligible for conventional treatment. For these patients, microencapsulated stem cells (SCs) offer a novel means to transplant mismatched therapeutic SCs to prevent graft immunorejection. Using c-arm CT and (19)F-MRI for serial evaluation of dual X-ray/MR-visible SC microcapsules (XMRCaps) in a non-immunosuppressed rabbit PAD model, we explore quantitative evaluation of capsule integrity as a surrogate of transplanted cell fate. MATERIALS AND METHODS: XMRCaps were produced by impregnating 12% perfluorooctylbromine (PFOB) with rabbit or human SCs (AlloSC and XenoSC, respectively). Volume and (19)F concentration measurements of XMRCaps were assessed both in phantoms and in vivo, at days 1, 8 and 15 after intramuscular administration in rabbits (n = 10), by 3D segmenting the injection sites and referencing to standards with known concentrations. RESULTS: XMRCap volumes and concentrations showed good agreement between CT and MRI both in vitro and in vivo in XenoSC rabbits. Injected capsules showed small variations over time and were similar between AlloSC and XenoSC rabbits. Histological staining revealed high cell viability and intact capsules 2 weeks after administration. CONCLUSIONS: Quantitative and non-invasive tracking XMRCaps using CT and (19)F-MRI may be useful to assess graft immunorejection after SC transplantation.
Journal Title: Magma (New York, N.Y.)
Volume: 32
Issue: 1
ISSN: 1352-8661
Publisher: Unknown  
Journal Place: Germany
Date Published: 2019
Start Page: 147
End Page: 156
Language: eng
DOI/URL:

10.1007/s10334-018-0728-2
Notes: LR: 20190312; GR: 2008-MDSCRFII-0399/Maryland Stem Cell Research Fund (US); GR: R33-HL089029/National Heart, Lung, and Blood Institute; JID: 9310752; OTO: NOTNLM; 2018/06/29 00:00 [received]; 2018/12/04 00:00 [accepted]; 2018/12/02 00:00 [revised]; 2018/12/12 06:00 [pubmed]; 2018/12/12 06:00 [medline]; 2018/12/12 06:00 [entrez]; ppublish